“…The reported results from three large randomized studies [11,20,23] combining B with chemotherapy showed improvement in PFS but not OS, and this was also confirmed in a recently presented pooled analysis of these three studies [12] and has led to a more critical re-evaluation of the added therapeutic value of B in MBC. The role of B in pre-treated metastatic disease has been evaluated in a few studies [10,25,26] with no effect on overall survival. In the RIBBON-2 study, which evaluated the combination of B with various chemotherapies (taxane, gemcitabine, capecitabine, or vinorelbine) to treat MBC in the second line, the addition of B improved PFS of HER2-negative MBC patients with differing clinical characteristics and disease histories [26].…”